The FDA approved the first nalmefene hydrochloride auto-injector (Zurnai) for use as an emergency treatment for opioid overdose in adults and children 12 years of age and older, the agency announced ...

Each single-dose Zurnai autoinjector delivers a dose of 1.5mg nalmefene (base) in 0.5mL. The Food and Drug Administration (FDA) has approved Zurnai ™, the first nalmefene HCl autoinjector for the ...

Addressing overdoses from “street drugs” containing potent synthetic opioids poses a key challenge when utilizing opioid antagonists. A standard approach to known or suspected opioid overdose includes ...

Purdue Pharma has asked the federal Food and Drug Administration (FDA) to approve a new, auto-injectable form of one of its drugs to treat opioid overdoses. The Stamford-based biopharmaceutical ...

Opioid antagonists are medications people can take to treat opioid use disorder. They help by reducing withdrawal symptoms, addressing cravings, and managing overdoses. Doctors prescribe opioid ...

Pharmacology: The use of opioid analgesics can lead to constipation due to their effect on intestinal smooth muscle and their interference with the bowel’s normal elimination function.

Please provide your email address to receive an email when new articles are posted on . Nalmefene can reduce the effects of opioid overdoses, like low BP, when administered quickly. Zurnai was ...

On August 7, the U.S. Food and Drug Administration (FDA) approved the nalmefene hydrochloride auto-injector that is used in the treatment of opioid overdose. The treatment is used to treat opioid ...

SILVER SPRING, Md., Aug. 7, 2024 /PRNewswire/ -- Today, the U.S. Food and Drug Administration approved Zurnai, the first nalmefene hydrochloride auto-injector for the emergency treatment of known or ...